Luyan Pharma released its 2026 interim report, with net profit attributable to the parent company of 143 million yuan, down 7.46% from the same period last year. Total operating revenue was 10.583 billion yuan, up 1.75% year on year, marking a fifth consecutive year of growth. Net cash flow from operating activities was negative 101 million yuan, down 147.98% from the same period last year. The company's latest asset-liability ratio was 74.77%, gross margin was 6.84%, return on equity was 4.32%, and diluted earnings per share was 0.37 yuan.
Luyan Pharma Co LtdNet profit fell 7.46% year on year, and operating cash flow turned deeply negative.
